Category - Markets

Leerink resumed coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and $25 price target. The stock finished at $13 on August 14. “We believe that at current levels the stock does not fully reflect the...

H.C. Wainwright upgraded Dicerna Pharmaceuticals (NASDAQ:DRNA) to “buy” from “neutral” and raised its price target to $21 from $14, citing broad progress across the company’s pipeline. The stock closed at $14.82 on...

JP Morgan upgraded Idera Pharmaceuticals (NASDAQ:IDRA) to “overweight” with a December 2019 price target of $15, following a period of restriction and a “not-rated” designation. JP Morgan had rated the stock, which...

Analysts for Leerink and JP Morgan initiated coverage for Replimune (NASDAQ:REPL) with “outperform” and “overweight” ratings, respectively. Leerink set its price target at $25 and JP Morgan at $26 for December 2019...

Mackie Research downgraded Correvio Pharma (NASDAQ:CORV) to “hold” from “speculative buy” but raised its price target to $4.70 from $3.30, citing the stock’s run up after a positive FDA announcement on the company’s...

Roth Capital Partners downgraded Gemphire Therapeutics (NASDAQ:GEMP) to “neutral” from “buy” with a $2 price target after the company terminated its Phase 2a pediatric non-alcoholic fatty liver disease (NAFLD) trial...

Ladenburg Thalmann lowered its price target for Scynexis (NASDAQ:SCNX) to $6 from $10, citing another delay in development of an IV formulation of ibrexafungerp. The stock closed at $1.39 on August 10. “As successful as...

JP Morgan initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with an “overweight” rating and $17 December 2019 price target. The stock closed at $9.85 on August 10. Analyst Anupam Rama writes that using...

Leerink launched coverage of Crinetics Pharma (NASDAQ:CRNX) with an “outperform” rating and a $43 price target. The stock closed at $30.68 on August 10. Crinetics is building a rare disease franchise in endocrinology...

Piper Jaffray downgraded Endologix (NASDAQ:ELGX) to “neutral” from “overweight” and lowered its price target to $4.75 from $7 after the company meaningfully reduced revenue guidance for the year as it moves to revamp...